Biosimilars Forum Calls For Further Action On Biden’s Competition Order
Impending Humira Launches Would Benefit From Increased Competition
Executive Summary
Generics Bulletin sits down with Biosimilars Forum executive director Julie Reed to discuss preparing the HHS for Humira biosimilars, what more the agency could do for the industry and the Forum’s priorities over the next year.
You may also be interested in...
US Biosimilar Impact Set To Overtake Small-Molecule Generics
The oncoming rush of biosimilars into the US pharmaceutical market is expected to exceed the impact of small molecule generic drugs for the first time, according to IQVIA research.
Humira One Year Out: The Largest LOE Event In US Pharma History
Ahead of the first biosimilar Humira product set to launch in 365 days, Generics Bulletin provides a comprehensive run-down of where biosimilar sponsors stand and the key issues ahead of market formation.
How Humira Finally Lost The Top Spot In Drug Sales
AbbVie’s Humira has been the world’s best-selling drug since 2012, and if it hadn’t been for COVID-19 it would most likely have been on track to retain its position for the 10th year in row.